Has Andrew Huberman confirmed he personally uses TRT?

Huberman has confirmed personal use of supplement and behavioral protocols targeting testosterone optimization, including tongkat ali and cold exposure. He has not made an unambiguous public statement confirming personal use of exogenous testosterone (injectable or otherwise). Online speculation exists, but this page does not treat speculation as confirmation.

What testosterone supplements has Huberman publicly recommended?

Huberman has publicly discussed tongkat ali (400 mg daily), fadogia agrestis (typically 600 mg daily, cycled), and boron (2 to 6 mg daily) as part of a testosterone-support supplement protocol. He has also discussed zinc, vitamin D, and ashwagandha in related contexts. Evidence quality varies significantly among these compounds.

Is TRT safe based on current evidence?

The 2023 TRAVERSE trial, the largest randomized controlled trial of TRT to date, found no increase in major adverse cardiovascular events in men aged 45 to 80 with hypogonadism and cardiovascular risk factors. TRT does carry known risks including erythrocytosis, fertility suppression, and possible worsening of sleep apnea. The Endocrine Society guidelines recommend TRT only for men with confirmed hypogonadism and appropriate monitoring.

Can supplements replace TRT for low testosterone?

For clinically diagnosed hypogonadism (total testosterone consistently below 300 ng/dL with symptoms), supplements are not a substitute for medical evaluation and treatment. Compounds like tongkat ali show modest effects in studies, but the magnitude of testosterone increase from supplements is far smaller than what pharmaceutical TRT provides. The appropriate intervention depends on baseline levels, symptoms, age, and fertility goals.

What bloodwork should be done before starting any testosterone protocol?

The HealthRX Medical Team recommends a minimum panel of two morning total testosterone draws (before 10 AM), free testosterone, SHBG, LH, FSH, estradiol, prolactin, complete blood count, comprehensive metabolic panel, and lipid panel. PSA should be included for men over 40. This baseline is essential whether pursuing pharmaceutical TRT or supplement-based optimization.

Andrew Huberman and TRT: The Documented Public Record

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Who: Andrew Huberman, Ph.D., tenured professor of neurobiology at Stanford School of Medicine
Drug family: Testosterone replacement therapy (TRT) and related hormone-optimization protocols
Status: Huberman has publicly confirmed personal use of supplement and behavioral protocols targeting testosterone optimization. He has discussed clinical TRT extensively with expert guests, though specific personal use of exogenous testosterone has not been unambiguously confirmed in public statements
Why it matters: The Huberman Lab podcast reaches millions of listeners per episode, making his commentary on hormone optimization one of the most influential public-facing sources on the topic
Clinical note: Behavioral and supplement-based testosterone optimization and pharmaceutical TRT are distinct interventions with different risk-benefit profiles

The Public Record: What Huberman Has Actually Said

Andrew Huberman's public commentary on testosterone spans years of podcast episodes, social media posts, and guest appearances. His approach blends neuroscience expertise with practical health optimization, and he frequently discusses hormones as part of a broader biological framework.

In multiple Huberman Lab episodes, he has outlined protocols he personally follows for testosterone support. These include cold exposure (deliberate cold water immersion), specific light exposure patterns, sleep optimization, resistance training, and targeted supplementation with compounds like tongkat ali (Eurycoma longifolia) and fadogia agrestis. He has stated on-air that he uses tongkat ali at 400 mg daily and has reported subjective benefits.

On clinical TRT itself, Huberman has hosted physicians including Dr. Kyle Gillett and Dr. Peter Attia for extended discussions of testosterone cypionate protocols, dosing ranges, monitoring bloodwork, and the downstream effects of exogenous testosterone on fertility and the hypothalamic-pituitary-gonadal (HPG) axis. During these episodes, Huberman asks detailed, specific questions that suggest deep familiarity with the clinical territory. He has referenced his own bloodwork values on multiple occasions, stating publicly that he monitors total testosterone, free testosterone, SHBG, estradiol, and other markers regularly.

Whether Huberman personally uses exogenous testosterone (injectable or otherwise) has been a subject of public speculation. He has not, as of the date of this review, made an unambiguous public confirmation of personal TRT use. His public statements center on supplement and behavioral optimization. Online communities frequently speculate about his protocols, but speculation is not confirmation, and this page treats the distinction seriously.

Clinical Context: What TRT Actually Does

Testosterone replacement therapy involves administering exogenous testosterone to men (and in some cases women) whose endogenous production is clinically insufficient. The Endocrine Society's 2018 clinical practice guidelines define male hypogonadism as a total testosterone level below 300 ng/dL on two morning samples, combined with signs or symptoms such as low libido, fatigue, reduced muscle mass, or mood disturbance.

The most common TRT formulations in the United States include:

Testosterone cypionate (intramuscular or subcutaneous injection): typical starting doses of 100 to 200 mg every 7 to 14 days
Testosterone enanthate: similar pharmacokinetics and dosing to cypionate
Transdermal testosterone (gels, patches): daily application, delivering approximately 50 to 100 mg of testosterone with variable absorption rates
Testosterone pellets (subcutaneous implant): placed every 3 to 6 months

The FDA's prescribing information for testosterone cypionate lists indicated use for conditions associated with deficiency or absence of endogenous testosterone production. The agency issued a 2015 safety communication cautioning against testosterone use for age-related decline alone, noting possible increased cardiovascular risk.

More recent data from the TRAVERSE trial, published in the New England Journal of Medicine in 2023, studied over 5,000 men aged 45 to 80 with hypogonadism and pre-existing or high risk for cardiovascular disease. The trial found that testosterone replacement did not increase the incidence of major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months. This trial significantly shifted the clinical conversation around cardiovascular safety of TRT.

Huberman's Supplement Stack: The Evidence Base

Huberman's publicly stated testosterone-support supplements deserve their own clinical scrutiny, since millions of listeners have adopted versions of his protocols.

Tongkat ali (Eurycoma longifolia): A 2012 randomized controlled trial of 76 men with late-onset hypogonadism found that 200 mg daily of a standardized water extract significantly improved testosterone levels, with 90.8% of the treatment group returning to normal reference ranges after one month. The effect sizes are modest. A 2022 systematic review confirmed small but statistically significant testosterone increases in men, though study quality was mixed.

Fadogia agrestis: This is where the evidence thins considerably. A 2005 animal study in rats showed dose-dependent increases in testosterone following oral administration of fadogia agrestis stem extract. No human randomized controlled trials exist for this compound. The same rat study noted testicular histological changes at higher doses, raising safety questions that remain unanswered in humans. Huberman has acknowledged this evidence gap publicly while still discussing the compound.

Boron: Huberman has mentioned boron supplementation at doses around 2 to 6 mg daily. A small 2011 study found that 10 mg of boron daily for one week increased free testosterone and decreased estradiol in healthy men. The sample size was eight participants. Replication in larger trials is limited.

The gap between these supplement studies and pharmaceutical TRT is vast. Clinical TRT reliably raises testosterone into the 500 to 1 to 000 ng/dL range depending on dose and formulation, while supplement effects, when present, are small and variable.

The HPG Axis: Why the Distinction Matters

One of Huberman's most valuable public contributions has been his repeated explanation of the hypothalamic-pituitary-gonadal axis. Understanding this feedback loop is essential for anyone evaluating TRT.

Gonadotropin-releasing hormone (GnRH) from the hypothalamus stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release from the anterior pituitary. LH acts on Leydig cells in the testes to produce testosterone. Exogenous testosterone administration suppresses this axis through negative feedback, reducing LH and FSH output and, consequently, intratesticular testosterone and spermatogenesis.

This is the core clinical trade-off of TRT: you gain reliable serum testosterone levels but at the cost of endogenous production and, in many cases, fertility. Huberman has discussed this trade-off extensively, including the use of human chorionic gonadotropin (hCG) as a co-therapy to maintain testicular function during TRT, and selective estrogen receptor modulators (SERMs) like clomiphene citrate as alternatives for men who want to preserve fertility.

Supplement-based approaches, by contrast, do not suppress the HPG axis because they either weakly stimulate endogenous production or have no direct interaction with the feedback loop at all. This distinction, which Huberman makes clearly in his episodes, is often lost in online discourse where "testosterone optimization" conflates fundamentally different interventions.

Side Effects and Monitoring

The clinical side effect profile of TRT includes:

Erythrocytosis (elevated hematocrit): the most common dose-limiting side effect, requiring monitoring via complete blood count every 6 to 12 months
Acne and oily skin: driven by increased dihydrotestosterone (DHT) conversion
Sleep apnea: may worsen in predisposed individuals
Gynecomastia: from peripheral aromatization of testosterone to estradiol
Testicular atrophy: secondary to HPG axis suppression
Mood changes: both improvements and, in some cases, increased irritability or aggression at supraphysiologic levels
Cardiovascular effects: the TRAVERSE data is reassuring for major events, though a secondary analysis showed higher rates of atrial fibrillation and acute kidney injury in the testosterone group

Huberman has addressed several of these effects on his podcast, particularly erythrocytosis and estrogen management via aromatase inhibitors, an area where his medical guests have offered varying opinions on the appropriateness of routine AI use alongside TRT.

The HealthRX Medical Team Take

Huberman's public discussions of testosterone science are, on balance, more rigorous than most influencer-grade health content. He references primary literature, explains mechanisms in detail, and generally distinguishes between proven interventions and emerging research. His willingness to name specific compounds and doses gives his audience actionable (if sometimes premature) information.

The HealthRX Medical Team notes several considerations for listeners adopting Huberman-influenced protocols:

First, behavioral and supplement interventions may produce measurable but clinically modest changes in testosterone. For a man with levels of 280 ng/dL and symptoms, cold exposure and tongkat ali are unlikely to substitute for medical evaluation and possible TRT. Conversely, for a man with levels of 450 ng/dL and no symptoms, pharmaceutical TRT carries risks that behavioral optimization does not.

Second, fadogia agrestis lacks human safety and efficacy data. Its widespread adoption based primarily on podcast recommendation and a single rat study represents a gap between Huberman's usual evidence standards and this specific recommendation.

Third, any discussion of hormone optimization should start with proper diagnostic workup, including two morning total testosterone draws, free testosterone, LH, FSH, SHBG, prolactin, and a metabolic panel, before any intervention. Huberman advocates for this, and the HealthRX Medical Team reinforces it as non-negotiable.

The broader cultural effect of Huberman's testosterone content is significant. He has normalized men discussing hormone health openly, pushed listeners toward evidence-based thinking (even when the evidence is incomplete), and created demand for more sophisticated clinical conversations between patients and their endocrinologists. The risk is that the sheer reach of his platform can amplify preliminary findings to an audience that may not parse confidence levels in the same way a trained scientist would.

Frequently asked questions

›